Table 2. Data on Drugs for Secondary Prevention at Baseline and During Follow-Up.
| LVEF < 50% (n† = 96/88/87) | LVEF ≥ 50% (n† = 416/393/391) | P value | |
|---|---|---|---|
| Aspirin | |||
| In-hospital, 512 | 92 (95.83%) | 402 (96.63%) | 0.710 |
| 1-year, 481 | 83 (94.32%) | 368* (93.64%) | 0.812 |
| 2-year, 478 | 82 (94.25%) | 367 (93.86%) | 0.890 |
| β-blockers | |||
| In-hospital, 512 | 83 (86.46%) | 365 (87.74%) | 0.723 |
| 1-year, 481 | 73 (82.95%) | 323* (82.19%) | 0.865 |
| 2-year, 478 | 71 (81.61%) | 321* (82.10%) | 0.915 |
| ACEIs/ARBs | |||
| In-hospital, 512 | 70 (72.92%) | 301 (72.36%) | 0.912 |
| 1-year, 481 | 66 (75.00%) | 289 (73.54%) | 0.778 |
| 2-year, 478 | 63 (72.41%) | 285 (72.89%) | 0.928 |
| Statins | |||
| In-hospital, 512 | 85 (88.54%) | 371 (89.18%) | 0.856 |
| 1-year, 481 | 74 (84.09%) | 332* (84.47%) | 0.928 |
| 2-year, 478 | 70 (80.46%) | 317* (81.07%) | 0.895 |
*P < 0.05, compared with in-hospital data within the LVEF ≥ 50% group. †The available number of patients in-hospital, and at 1- and 2-year follow-up. ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin II receptor blockers; LVEF: left ventricular ejection fraction.